evekhm/cms_iom_500 huggingface dataset:
Article - Billing and Coding: Infliximab and biosimilars (A52423)
FDA and Compendia Review:American Society of Health-System Pharmacists, Inc.AHFS Drug Information.Bethesda, MD: 2007.Clinical Pharmacology Web site. http://www.clinicalpharmacology.com/. Accessed 09/05/2022.FDA label for infliximab-dyyb (Inflectra). FDA Web site: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed on 06/08/2016FDA label for infliximab-abda (Renflexis). FDA Web site: https://www.accessdata.fda.gov/scripts/cder/daf/index. Accessed on 08/21/2017.FDA label for inflizimab-axxq (Avsola). FDA Web site: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed on 07/14/2020.Lexi-Drugs Web site. http://online.lexi.com. Accessed 09/05/2022.Micromedex DrugDex. Thomson Web site. http://www.thomsonhc.com/home/dispatch. Accessed 09/05/2022.National Comprehensive Cancer Network Web site. http://www.nccn.org/index.asp. Accessed 09/05/2022.U.S. Food and Drug Administration label approved 08/24/1998 accessed on line athttp://www.accessdata.fda.gov/scripts/cder/drugsatfda/ on 02/01/2008.United States Pharmacopoeia (USP), Volume I; Drug Information for the Health Care Professional, 2007.
Article - Clinical Trials – Medical Policy Article (A52430)
CMS National Coverage PolicyN/AArticle TextAbstract:From the inception of the Medicare program, items and services that were deemed "experimental or investigational" were statutorily excluded from Medicare coverage. In recent years, there has been a growing number of exceptions to this statutory exclusion, and the rules for coverage under these exceptions have become increasingly complex. Currently, Medicare coverage is available for Category B Investigational Devices, services under CMS' Coverage with Evidence Development trials, and other qualifying clinical trials. CMS National Coverage Determination (NCD) for Routine Costs in Clinical Trials (CMS Pub.100-03, Section 310.1) provides instructions for coverage of these clinical trials. This article summarizes and discusses Medicare coverage of the routine costs of these other qualifying trials.In 2000, President Clinton issued an executive order directing CMS to cover the "routine costs" of clinical trials for Medicare beneficiaries. These routine costs include the provision of the investigational item, but not the investigational item itself, the prevention, diagnosis, and treatment of complications, and generally all items and services that would be covered for a Medicare beneficiary absent the clinical trial.Indications:There are several criteria for which clinical trials are eligible for coverage of their routine costs.Trials that are deemed to be automatically qualified include:trials funded by NIH, CDC, AHRQ, CMS, DOD, and VA;trials supported by centers or cooperative groups that are funded by NIH, CDC, AHRQ, CMS, DOD, and VA;trials conducted under an investigational new drug application (IND) reviewed by the FDA; orIND exempt drug trials under 21 CFR 312.2(b)(1) will be deemed automatically qualified until the self-certification process is in place.</ul type=disc>Other clinical trials, not falling into the above categories, must meet all the following requirements:The trial must evaluate an item or service that falls within a Medicare benefit categoryThe trial must not be designed exclusively to test toxicity or disease pathophysiology. It must have a therapeutic intentTrials of therapeutic interventions must enroll patients with diagnosed disease, not healthy volunteers</ul type=disc>Note: Trials of diagnostic interventions may enroll healthy patients as a control group.
Article - Clinical Trials – Medical Policy Article (A52430)
In addition to these requirements, covered clinical trials should have the following desirable characteristics:Tests whether the intervention potentially improves the participants' health outcomesIs well supported by available scientific literature, or is intended to clarify the health outcomes of interventions already in common clinical useDoes not unjustifiably duplicate existing studiesDesign is appropriate to answer the research questionIs sponsored by a credible organization or individualIs in compliance with Federal regulations on protection of human subjectsAll aspects are conducted according to the appropriate standards of scientific integrity</ul type=disc>The local contractor may provide assistance in determining whether a clinical trial that is not automatically deemed to qualify meets Medicare requirements for coverage of routine costs.In general, the routine costs of a clinical trial include those costs that a Medicare beneficiary would be eligible for if there were no clinical trial. This principle tries to ensure that Medicare beneficiaries are not penalized nor have items or services taken away from them if they participate in a qualifying clinical trial. These routine costs include:Items or services typically provided absent a clinical trial (e.g., conventional care);Items or services required solely for the provision of the investigational item or service;Clinically appropriate monitoring of the effects of the investigational item or service;Prevention of complications; andItems or services for reasonable and necessary care arising from the provision of an investigational item or service, especially for the diagnosis and treatment of complications.</ul type=disc>Limitations:
Article - Clinical Trials – Medical Policy Article (A52430)
Items and services not covered as "routine services" in a clinical trial include:The investigational item or service itself, unless otherwise covered outside the clinical trial;Items and services for the purpose of determining eligibility for the study not related to medically necessary clinical care;Items and services provided solely to satisfy data collection and not necessary for clinical management; andItems and services customarily provided by the research sponsors free of charge for any enrollee in the trial.</ul type=disc>The investigational items or services themselves are not covered as routine costs, unless those items or services are available to Medicare beneficiaries absent a clinical trial. For instance, if a qualifying clinical trial is studying a drug for a non-FDA approved indication, the drug is not covered because it is not otherwise available to Medicare beneficiaries for that experimental indication, even if the drug is FDA approved for other indications. Conversely, if an investigator is doing a head-to-head study of two standard-of-practice procedures to see which one is superior in a given circumstance, then the procedures under study are also covered, even though they are the "experimental service," because these services are otherwise covered for Medicare beneficiaries.Items and services provided solely for data collection are important non-routine costs to separate out from the costs constituting the standard of care. Patients in clinical trials often have laboratory and radiological studies which exceed the requirements for the ordinary clinical care of a patient because the requirements for the study's data collection are higher than what is required for the clinical care of the patient (e.g., monthly CT scans for a condition usually requiring only a single scan). All the tests and services in excess of what is required for ordinary clinical care are considered non-routine, and are not covered. Providers should document which items and services are required as a part of ordinary clinical care, which are required in addition to meet the data collection requirements of the study, and should bill these respectively as covered or noncovered, respectively. Documentation of covered vs. noncovered services for each study will support the appropriateness of the bills submitted to Medicare, should these services be reviewed.
Article - Clinical Trials – Medical Policy Article (A52430)
Items and services customarily provided by the research sponsors free of charge for any enrollee in the trial should likewise not be billed to Medicare. Items and services provided regularly free of charge to any segment of the study's enrollees are not included as routine costs and are not dependent on payer type. For example, because Medicare may pay for certain costs in the study, but other payers will not and the study sponsor provides those items or services for free to those study participants, then Medicare likewise must not be billed for those items and services. Medicare's potential willingness to pay for an item or service does not determine whether that item or service is covered. Medicare must be on a level playing field with all payer types regarding billing for the routine costs in clinical trials. The one exception to this rule is for patients who are indigent and for whom the hospital routinely offers care without payment. Services to such individuals who do not have the ability to pay and for whom the hospital policy is to provide free care would not inhibit the hospital from billing Medicare for those same items and services it has furnished to these individuals without reimbursement.Other items and services not covered as routine costs include otherwise non-covered items and services, including items and services for which payment is statutorily prohibited, unless required for the treatment of complications. Guidance from the contractor may be required to determine if such treatment of complications are covered. Also, investigational items and services in a qualifying clinical trial that are not covered by virtue of a NCD remain not covered for patients in the trial, although the routine costs may still be covered. In addition, coverage of routine costs in a clinical trial is subject to any applicable coverage provisions in the contractor's local coverage determinations that may be in effect.Providers are expected to review the items and services that may be billed to Medicare for each qualifying clinical trial they participate in and to make a determination for each item and service, whether it is covered or not covered under these rules. For unusual situations for which the provider may be unable to make their own determination, the Medicare contractor to which you submit your claims may be of assistance.Utilization:Not applicableDocumentation Requirements:The medical record must contain documentation that the services billed to Medicare meet the criteria defined in the Indications and Limitations section of this article.
Article - Clinical Trials – Medical Policy Article (A52430)
Utilization:Not applicableDocumentation Requirements:The medical record must contain documentation that the services billed to Medicare meet the criteria defined in the Indications and Limitations section of this article.In addition, documentation must be available in the medical record of covered vs. noncovered services for each study that will support the appropriateness of the bills submitted to Medicare, should these services be reviewed.Coding Guidelines:General Guidelines for claims submitted to Part A or Part B MAC:Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. Refer to NCCI and OPPS requirements prior to billing Medicare.For services requiring a referring/ordering physician, the name and NPI of the referring/ordering physician must be reported on the claim.The diagnosis code(s) must best describe the patient's condition for which the service was performed.A claim submitted without a valid ICD-10-CM diagnosis code will be returned to the provider as an incomplete claim under Section 1833(e) of the Social Security Act.Providers should enter clinical trial and non-clinical trial services on separate lines when both types of services are submitted on the same claim form.Items and services provided free of charge by research sponsors should not be billed to Medicare. If these items are required for payment of another payable service, providers should submit the items as non-covered (use modifiers FB and GX or GY). For OPPS claims, a token charge must be entered on the line for a no-cost item.Advance Beneficiary Notice of Noncoverage (ABN) Modifier GuidelinesAn ABN may be used for services which are likely to be non-covered, whether for medical necessity or for other reasons. Refer to CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 30, for complete instructions.Effective from April 1, 2010, non-covered services should be billed with modifier GA, -GX, -GY, or GZ, as appropriate.
Article - Clinical Trials – Medical Policy Article (A52430)
Effective from April 1, 2010, non-covered services should be billed with modifier GA, -GX, -GY, or GZ, as appropriate.The GA modifier (Waiver of Liability Statement Issued as Required by Payer Policy) should be used when physicians, practitioners, or suppliers want to indicate that they anticipate that Medicare will deny a specific service as not reasonable and necessary and theydo havean ABN signed by the beneficiary on file. Modifier GA applies only when services will be denied under reasonable and necessary provisions, sections1862(a)(1), 1862(a)(9) , 1879(e), or 1879(g)of the Social Security Act. Effective April 1, 2010, Part A MAC systems will automatically deny services billed with modifier GA. An ABN, Form CMS-R-131, should be signed by the beneficiary to indicate that he/she accepts responsibility for payment. The -GA modifier may also be used on assigned claims when a patient refuses to sign the ABN and the latter is properly witnessed. For claims submitted to the Part A MAC, occurrence code 32 and the date of the ABN is required.Modifier GX (Notice of Liability Issued, Voluntary Under Payer Policy) should be used when the beneficiary has signed an ABN, and a denial is anticipated based on provisionsotherthan medical necessity, such as statutory exclusions of coverage or technical issues. An ABN is not required for these denials, but if non-covered services are reported with modifier GX, Part A MAC systems will automatically deny the services.The GZ modifier should be used when physicians, practitioners, or suppliers want to indicate that they expect that Medicare will deny an item or service as not reasonable and necessary and theyhave nothad an ABN signed by the beneficiary.If the service is statutorily non-covered, or without a benefit category, submit the appropriate CPT/HCPCS code with the -GY modifier. An ABN is not required for these denials, and the limitation of liability does not apply for beneficiaries. Services with modifier GY will automatically deny.For claims submitted to the Part B MAC:
Article - Clinical Trials – Medical Policy Article (A52430)
For claims submitted to the Part B MAC:Routine costs of a clinical trial should be submitted to the Part B MAC as follows:For dates of service on or after January 1, 2008, report modifier "Q1" with each service. The primary diagnosis must be Z00.6.For dates of service prior to January 1, 2008, report modifier "QV" with each service. The primary diagnosis on the claim must be Z00.6As of April 1, 2008, providers have the option of reporting the 8-digit clinical trial number on the claim in item 19 of the CMS 1500 or electronic equivalent. However, this number is not required.</ul type=disc>For claims submitted to the Part A MACRoutine costs of a clinical trial should be submitted to the Part A MAC as follows:Diagnosis Z00.6 must be reportedCondition code 30 is also required on institutional claims, regardless of whether all services on the claim are related to the clinical trial or not.Modifiers QV or Q1 are not required on institutional claims, unless the claim includes clinical trial and non-clinical trial services (for outpatient claims). In this case, modifiers Q1 (on or after January 1, 2008) or QV (prior to January 1, 2008) must be reported with the clinical trial related services.As of April 1, 2008, providers have the option of reporting the 8-digit clinical trial number on the claim in FL 39-41 of the UB-04 or electronic equivalent. However, this is not required.</ul type=disc>Hospital Inpatient Claims:
Article - Clinical Trials – Medical Policy Article (A52430)
The hospital should report the patient's principal diagnosis in Form Locator (FL) 67 of the UB-04.The principal diagnosis is the condition established after study to be chiefly responsible for this admission.For routine costs associated with clinical trials, this diagnosis will be Z00.6.The hospital enters ICD-10-CM codes for up to eight additional conditions in FLs 67A-67Q if they co-existed at the time of admission or developed subsequently, and which had an effect upon the treatment or the length of stay. It may not duplicate the principal diagnosis listed in FL 67.For inpatient hospital claims, the admitting diagnosis is required and should be recorded in FL 69. (See CMS Publication 100-04,Medicare Claims Processing Manual, Chapter 25, Section 75 for additional instructions.)</ul type=disc>Hospital Outpatient Claims:The hospital should report the full ICD-10-CM code for the diagnosis shown to be chiefly responsible for the outpatient services in FL 67.If no definitive diagnosis is made during the outpatient evaluation, the patient's symptom is reported. If the patient arrives without a referring diagnosis, symptom or complaint, the providershould report an ICD-10-CM code for Persons Without Reported Diagnosis Encountered During Examination and Investigation of Individuals and Populations (Z00.00-Z13.9). For routine costs associated with clinical trials, this diagnosis will be Z00.6.The hospital enters the full ICD-10-CM codes in FLs 67A-67Q for up to eight other diagnoses that co-existed in addition to the diagnosis reported in FL 67.</ul type=disc>For dates of service prior to April 1, 2010, FQHC services should be reported with bill type 73X. For dates of service on or after April 1, 2010, bill type 77X should be used to report FQHC services.
Article - Billing and Coding: Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach (0192T 66183) (A52432)
CMS National Coverage PolicyN/AArticle TextAbstract:Glaucoma filtering surgery is indicated when glaucomatous damage progresses despite pharmacological and/or surgical treatment. Trabeculectomy is the most widely used form of filtering surgical treatment for primary open-angle glaucoma. Glaucoma drainage implants designed to shunt the aqueous fluid posteriorly represent an alternative method for lowering intraocular pressure in glaucomatous patients and are commonly used in refractory glaucoma or after failure of filtration surgery.Since the first mini shunt device was approved by the Food and Drug Administration (FDA) for marketing in March 2002, over 14,000 implantations have been performed. However, there has been disagreement in the ophthalmology community regarding the correct coding for this procedure. The majority of ophthalmologists billed Current Procedural Terminology (CPT) code66180 (Aqueous shunt to extraocular reservoir [eg, Molteno, Schocket, Denver-Krupin]), with some using 66172 (Fistulization of sclera for glaucoma; trabeculectomy ab externo with scarring from previous ocular surgery or trauma [includes injection of antifibrotic agents]) or 66999 (Unlisted procedure, anterior segment of eye).Because of this disagreement, the American Medical Association (AMA) CPT Panel developed a new Category III CPT code,0192T (Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach),effective for services rendered on or after July 1, 2008 thru December 31, 2013. Effective January 1, 2014 CPT code 66183 should be used for the insertion of anterior segment aqueous drainage device.. The appropriate ICD-10-CM codes are listed below in the covered ICD-10 code section. The device used must be FDA approved, such as the Ex-PRESS mini shunt (Optonol).Indications:
Article - Billing and Coding: Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach (0192T 66183) (A52432)
Indications:An anterior segment aqueous drainage device, without extraocular reservoir, implanted under a partial thickness scleral flap may be a safe alternative or adjunct to standard guarded trabeculectomy, especially for patients with advanced glaucoma in need of low intraocular pressures with a high risk for hypotonous complication.Limitations:Other indications for 0192T and/or 66183 remain investigational or not medically necessary.Coding Guidelines:General Guidelines for claims submitted to Part A or Part B MAC:Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. Refer to NCCI and OPPS requirements prior to billing Medicare.For services requiring a referring/ordering physician, the name and NPI of the referring/ordering physician must be reported on the claim.A claim submitted without a valid ICD-10-CM diagnosis code will be returned to the provider as an incomplete claim under Section 1833(e) of the Social Security Act.The diagnosis code(s) must best describe the patient's condition for which the service was performed.Advance Beneficiary Notice of Noncoverage (ABN) Modifier GuidelinesAn ABN may be used for services which are likely to be non-covered, whether for medical necessity or for other reasons. Refer to CMS Publication 100-04,Medicare Claims Processing Manual, Chapter 30, for complete instructions.Effective from April 1, 2010, non-covered services should be billed with modifier GA, -GX, -GY, or GZ, as appropriate.
Article - Billing and Coding: Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach (0192T 66183) (A52432)
Effective from April 1, 2010, non-covered services should be billed with modifier GA, -GX, -GY, or GZ, as appropriate.The GA modifier (Waiver of Liability Statement Issued as Required by Payer Policy) should be used when physicians, practitioners, or suppliers want to indicate that they anticipate that Medicare will deny a specific service as not reasonable and necessary and theydo havean ABN signed by the beneficiary on file. Modifier GA applies only when services will be denied under reasonable and necessary provisions, sections1862(a)(1), 1862(a)(9), 1879(e), or 1879(g)of the Social Security Act. Effective April 1, 2010, Part A MAC systems will automatically deny services billed with modifier GA. An ABN, Form CMS-R-131, should be signed by the beneficiary to indicate that he/she accepts responsibility for payment. The -GA modifier may also be used on assigned claims when a patient refuses to sign the ABN and the latter is properly witnessed. For claims submitted to the Part A MAC, occurrence code 32 and the date of the ABN is required.Modifier GX (Notice of Liability Issued, Voluntary Under Payer Policy) should be used when the beneficiary has signed an ABN, and a denial is anticipated based on provisionsotherthan medical necessity, such as statutory exclusions of coverage or technical issues. An ABN is not required for these denials, but if non-covered services are reported with modifier GX, Part A MAC systems will automatically deny the services.The GZ modifier should be used when physicians, practitioners, or suppliers want to indicate that they expect that Medicare will deny an item or service as not reasonable and necessary and theyhave nothad an ABN signed by the beneficiary.If the service is statutorily non-covered, or without a benefit category, submit the appropriate CPT/HCPCS code with the -GY modifier. An ABN is not required for these denials, and the limitation of liability does not apply for beneficiaries. Services with modifier GY will automatically deny.